Actinium Pharmaceuticals
ATNM
43 hedge funds and large institutions have $3.42M invested in Actinium Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
2% more funds holding
Funds holding: 42 → 43 (+1)
0.04% less ownership
Funds ownership: 0.29% → 0.25% (-0.04%)
52% less capital invested
Capital invested by funds: $7.11M → $3.42M (-$3.69M)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$432K |
| 2 |
SCM
Sio Capital Management
New York
|
+$193K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$113K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$91.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$816K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$404K |
| 3 |
Renaissance Technologies
New York
|
-$194K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$79.7K |
| 5 |
VF
Virtu Financial
New York
|
-$63.4K |
ATNM Hedge Fund Activity: Q4 2018 in Review
43 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2018, worth a combined $3.42M — down 52% from $7.11M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATNM positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $432K. The largest seller was Essex Investment Management, exiting entirely with an estimated $816K sold.
- 43 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2018, up from 42 in Q3 2018.
- Funds reported $3.42M of Actinium Pharmaceuticals stock for Q4 2018, down 52% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q4 2018 and 4 closed out, a net change of +2 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $432K added.
- The largest Actinium Pharmaceuticals seller in Q4 2018 was Essex Investment Management, an estimated $816K sold.
Based on aggregated 13F filings for Q4 2018.